Nasdaq Extends Medirom's Deadline to November 11 for Filing Delayed Annual Report
MRM is trading near its 52-week low of $0.87 (0.0% above the low).
Summary
Nasdaq has given Medirom until November 11, 2026, to file its delayed 2025 annual report and regain compliance. Failure to meet this deadline will lead to delisting.
Key Events · Legal and Risk Events · MRM
-
Nasdaq Extension Granted
After Medirom submitted a compliance plan, Nasdaq extended the deadline to regain compliance with listing rules to November 11, 2026.
-
Delisting Risk Remains
If the 2025 Form 20-F is not filed by the new deadline, Nasdaq will notify the company that its ADSs will be delisted, though Medirom may appeal.
-
Stock Near 52-Week Low
Shares trade at $0.87, near the 52-week low, reflecting market concerns about the company's financial reporting and listing status.
-
Prior Non-Compliance Notice
The original Nasdaq notice was received on May 26, 2026, due to the delayed filing of the 2025 annual report.
Analysis · MRM · Trade & Services
A critical reprieve has arrived for Medirom: Nasdaq has pushed back the deadline for its overdue 2025 annual report to November 11, 2026. The company has been out of compliance since May 26, and missing this new cutoff would immediately trigger delisting proceedings. While the extension offers breathing room, the stock is languishing near its 52-week low of $0.87—a clear signal of deep market skepticism about the company's ability to resolve its reporting failures. Governance concerns are mounting, and the delisting threat remains acute.
At the time of this filing, MRM was trading at $0.87 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.87 to $4.45. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.